贵州医药
貴州醫藥
귀주의약
GUIZHOU MEDICAL JOURNAL
2014年
8期
679-681
,共3页
李安洁%唐峰%蒋智%王咏梅%龙向淑%况立洪
李安潔%唐峰%蔣智%王詠梅%龍嚮淑%況立洪
리안길%당봉%장지%왕영매%룡향숙%황립홍
急性冠脉综合征%阿托伐他汀钙%高敏C反应蛋白%血脂
急性冠脈綜閤徵%阿託伐他汀鈣%高敏C反應蛋白%血脂
급성관맥종합정%아탁벌타정개%고민C반응단백%혈지
Acute coronary syndrome%Atovastatin%Calcium high sensitivity c-reactive protein%Blood lipid
目的:比较不同剂量阿托伐他汀钙对急性冠脉综合征(ACS)患者的血脂及高敏C反应蛋白(hs-CRP)的影响。方法将200例住院ACS患者随机分为A组(100例):每晚口服阿托伐他汀钙20mg ,B组(100例):每晚口服阿托伐他汀钙40mg。比较服药前及服药后第4周、8周两组患者血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C))、hs-CRP水平及药物不良反应发生率。结果治疗4周后,两组患者血清TC、LDL-C及hs-CRP水平较治疗前均明显下降(均 P<0.05),TG组间比较尚无显著差异,LDL-C及hs-CRP组间比较有差异。治疗8周后B组患者血清TC、LDL-C和hs-CRP的降低显著大于A组[(3.53±0.45) vs (4.07±0.54);(1.86±0.44) vs (2.25±0.45);(7.13±5.21) vs (12.48±5.72),均 P<0.05)]。HDL-C两组均明显升高(均 P<0.05),而B组升高显著大于 A 组[(1.65±0.45)vs (1.48±0.47),P<0.05)]。两组药物不良反应发生率无显著差异( P>0.05)。结论40mg较20mg阿托伐他汀钙,能进一步降低血清TC、LDL-C及hs-CRP水平,斑块稳定性可能更强,而安全性相当。
目的:比較不同劑量阿託伐他汀鈣對急性冠脈綜閤徵(ACS)患者的血脂及高敏C反應蛋白(hs-CRP)的影響。方法將200例住院ACS患者隨機分為A組(100例):每晚口服阿託伐他汀鈣20mg ,B組(100例):每晚口服阿託伐他汀鈣40mg。比較服藥前及服藥後第4週、8週兩組患者血清總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C))、hs-CRP水平及藥物不良反應髮生率。結果治療4週後,兩組患者血清TC、LDL-C及hs-CRP水平較治療前均明顯下降(均 P<0.05),TG組間比較尚無顯著差異,LDL-C及hs-CRP組間比較有差異。治療8週後B組患者血清TC、LDL-C和hs-CRP的降低顯著大于A組[(3.53±0.45) vs (4.07±0.54);(1.86±0.44) vs (2.25±0.45);(7.13±5.21) vs (12.48±5.72),均 P<0.05)]。HDL-C兩組均明顯升高(均 P<0.05),而B組升高顯著大于 A 組[(1.65±0.45)vs (1.48±0.47),P<0.05)]。兩組藥物不良反應髮生率無顯著差異( P>0.05)。結論40mg較20mg阿託伐他汀鈣,能進一步降低血清TC、LDL-C及hs-CRP水平,斑塊穩定性可能更彊,而安全性相噹。
목적:비교불동제량아탁벌타정개대급성관맥종합정(ACS)환자적혈지급고민C반응단백(hs-CRP)적영향。방법장200례주원ACS환자수궤분위A조(100례):매만구복아탁벌타정개20mg ,B조(100례):매만구복아탁벌타정개40mg。비교복약전급복약후제4주、8주량조환자혈청총담고순(TC)、감유삼지(TG)、저밀도지단백담고순(LDL-C)、고밀도지단백담고순(HDL-C))、hs-CRP수평급약물불량반응발생솔。결과치료4주후,량조환자혈청TC、LDL-C급hs-CRP수평교치료전균명현하강(균 P<0.05),TG조간비교상무현저차이,LDL-C급hs-CRP조간비교유차이。치료8주후B조환자혈청TC、LDL-C화hs-CRP적강저현저대우A조[(3.53±0.45) vs (4.07±0.54);(1.86±0.44) vs (2.25±0.45);(7.13±5.21) vs (12.48±5.72),균 P<0.05)]。HDL-C량조균명현승고(균 P<0.05),이B조승고현저대우 A 조[(1.65±0.45)vs (1.48±0.47),P<0.05)]。량조약물불량반응발생솔무현저차이( P>0.05)。결론40mg교20mg아탁벌타정개,능진일보강저혈청TC、LDL-C급hs-CRP수평,반괴은정성가능경강,이안전성상당。
Objective To observe effects of Atovastatin Calcium (Ato) of higher dose on inflam-mation and blood lipid in patients with acute coronary syndrome (ACS) .Methods Two hundred pa-tients with ACS were randomly divided into two groups which were group A (Ato 20 mg/d) and group B (Ato 40 mg/d) .The treatment was lasted for 8 weeks .high-sensitivity c-reactive protein (hs-CRP) and blood lipid were tested and compared before and 4 ,8 weeks after treatment .Results Total choles-terol (TC) ,low -density lipoprotein cholesterol (LDL-C) and the hs-CRP levels were significantly lower (P<0 .05) 4 weeks after treatment ,but there was no significant difference between TG groups A and groups B .8 weeks after treatment TC ,LDL-C and hs-CRP in group B was significantly lower than that in group A [(3 .53 ± 0 .45) vs (4 .07 ± 0 .54) ,(1 .86 ± 0 .44) vs (2 .25 ± 0 .45) ,(7 .13 ± 5 .21) vs (12 .48 ± 5 .72) ,(all P<0 .05)] ,high density lipoprotein cholesterol (HDL-C) in the two groups was significantly higher (P<0 .05) ,and was significantly higher in group B than in group A[(1 .65 ± 0 .45) vs (1 .48 ± 0 .47) ,P<0 .05)] .Conclusion Effects of 40 mg/d Ato were better than 20 mg/d Ato on the patients with ACS .